Drugs / IASO208
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07309900 | Nov 2025 → Dec 2028 expected | B-cell neoplasm | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-16 | Nanjing IASO Biotechnology Co., Ltd. | IASO Bio’s CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance iasobio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IASO208 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07309900 ↗ |